Women’s Health Policy

The Trump Administration has taken numerous steps to significantly alter the Title X program, the federal grant program that supports family planning services to low-income women. This brief provides an overview of the Title X program, discusses the new 2018 funding announcement and related litigation, and reviews the Trump Administration’s proposed regulations and the implications of these changes.

This brief provides an overview of oral contraception, discusses private insurance and Medicaid coverage, and reviews strategies to promote and expand women’s access to oral contraceptives.

This map presents the share of Title X clinics that are Planned Parenthood clinics and/or provide abortions (as of 05/2019) and would no longer qualify for funding unless they separate from Planned Parenthood Federation of America or physically separate their abortion services from their family planning care.

The first FDA-approved over-the-counter daily oral contraceptive pill in the United States— Perrigo’s Opill— is now available for pre-order at major online retailers and will soon be available in stores. Although the new over-the-counter pill could broaden access to contraceptive options in the United States, KFF research suggests consumers are…

KFF recently updated its interactive dashboard with national and state data on women’s health, as well as information about various policies that affect women’s health. The dashboard provides instant access the most up-to-date state level indicators of women’s health in the U.S. Many of the indicators also provide national and…

With federal regulators seeking public input on the potential benefits, costs, and implementation considerations of requiring private health insurance plans to cover over-the-counter preventive products without a prescription, a new KFF post explores the issues relevant to covering over-the-counter contraceptives. These contraceptives include Opill, the first daily oral contraceptive pill…

As Opill—the first over-the-counter daily oral contraceptive pill in the United States—is expected to be available for purchase in early 2024, new research conducted by KFF examines barriers to its accessibility for consumers and challenges in providing insurance coverage for it. Based on interviews with nearly 80 representatives from private…

In a new brief, KFF examines how the Comstock Act, an 1873 anti-vice law banning the mailing of obscene matter and articles, could be used by an anti-abortion presidential administration to sharply restrict the availability of abortion nationwide.  The Biden Administration’s Department of Justice has said the Comstock Act should…

A new KFF survey of office-based OBGYNs finds widespread effects on their practices and patients since the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization one year ago.  In states with abortion bans, half say that they have patients who have been unable to obtain an abortion, about…

Following the Supreme Court’s ruling overturning Roe v. Wade, uncertainty has emerged over whether the right to contraception could also be limited. Justice Thomas’ concurring opinion in Dobbs renewed attention and raised the possibility that other Supreme Court precedents relying on the same principles as Roe, such as the right…